LIQUADD®

Brand Name: Liquadd® Approval Date: 03/11/2008
Generic Name: Dextroamphetamine Sulfate AWP: $174.99/473mL
Dosage Form: Oral Solution $1.85/5mL
Manufacturer: Auriga Laboratories, Inc. Generic Available: No
Strength: 5mg/5mL solution Acute/Maintenance: Maintenance
Description: Liquadd® (dextroamphetamine sulfate) oral solution 5mg/5mL. This is the first and
only available oral liquid formulation of dextroamphetamine.
Indication: Liquadd® is indicated for the treatment of Attention Deficit Hyperactivity Disorder
(ADHD) in patients aged 3 years and older.
Dosage Administration: Amphetamines should be administered at the lowest effective dosage
and dosage should be individually adjusted. Late evening doses should be avoided because of
the resulting insomnia. The usual amphetamine dosing for ADHD is 2.5mg to 40mg daily in
patients <12 and up to 60mg in adults, given in one to two doses.
Drug Interactions/Side Effects/Cautions: Amphetamines have a high potential for abuse.
Administration of amphetamines for prolonged periods of time may lead to drug dependence and
must be avoided. Particular attention should be paid to the possibility of subjects obtaining
amphetamines for non-therapeutic use or distribution to others, and the drugs should be
prescribed or dispensed sparingly. Misuse of amphetamines may cause sudden death and
serious cardiovascular adverse events.
Do not use Liquadd® in patients with a history of drug abuse. Do not use during or within 14 days
following administration of MAO inhibitors; hypertensive crisis may result. Liquadd® is
contraindicated in patients with advance arteriosclerosis, symptomatic cardiovascular disease,
moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the
sympathomimetic amines, glaucoma and agitated states.
Alternative Formulary Agents in Class: Dexedrine® (dextroamphetamine sulfate) capsule,
Dextrostat® (dextroamphetamine sulfate) tablet, dextroamphetamine (generic form) capsules and
tablets.